This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Close
Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Avastin® (bevacizumab)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼(pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozyltrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Immunology
      • RoACTEMRA® (tocilizumab)
      • Haematology
      • Gazyvaro® (obinutuzumab)
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab)
      • Esbriet® (pirfenidone)
      • GAZYVARO® (obinutuzumab)
      • HEMLIBRA®▼(emicizumab)
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab)
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • RoACTEMRA® (tocilizumab) RA/GCA
      • RoACTEMRA® (tocilizumab) pJIA/sJIA
      • RoACTEMRA® (tocilizumab) CRS
      • Rozlytrek® ▼(entrectinib)
      • Tecentriq®▼ (atezolizumab) HCC
      • Tecentriq®▼ (atezolizumab) Lung Cancer
      • Tecentriq®▼ (atezolizumab) mTNBC
      • Tecentriq®▼ (atezolizumab) mUC
    • Adverse Events Reporting
      Adverse Events Reporting Overview
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    • Neuroscience. Neuroscience is a major focus of research and development at Roche. The company’s goal is to develop treatment options based on the biology of the nervous system to help improve the lives of people with chronic and potentially devastating diseases.

      Neuroscience

      Neuroscience is a major focus of research and development at Roche. The company’s goal is to develop treatment options based on the biology of the nervous system to help improve the lives of people with chronic and potentially devastating diseases.

      Read more

    • Neuroscience
    • Roche in MS
    • ABN 2020
    • ECTRIMS 2019
    • More
      • Roche in MS
      • ABN 2020
      • ECTRIMS 2019

    You are here:

    1. Therapy Areas
    2. Neuroscience

    We are committed to Neuroscience

    Our scientists are at the forefront in advancing the way we think about the brain and how we treat it. We believe the future of neuroscience lies in detecting and treating illness early to help prevent degeneration and disease progression.

    Roche has a strong commitment to R&D. We have 66 new medicines in development, 13 of which are in neuroscience.1

    • Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.2
    • £8.4 billion invested globally in R&D in 2017 and £388 million within the UK.3
    • 10,600 UK patients participated in Roche clinical trials in 2017.3

    Roche in MS

    • 21.09.2020

      Roche is committed to working with partners to support the MS community.

      More

    ABN 2020

    • ABN Virtual Meeting 2020

      28.09.2020

      ABN 2020

      Take a look at the Roche data presented at virtual ABN 2020.

      More

    ECTRIMS 2019

    • 12.08.2020

      ECTRIMS 2019

      Learn more about the key data highlights presented at ECTRIMS 2019 and how they could impact UK clinical practice.

      More

    MS, multiple sclerosis; R&D, research and development.

     

    Reference:

    1. https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm. Last accessed September 2020.
    2. Investors Update July 2020.
    3. Roche Impact in the UK 2018: Core Claims Document. F. Hoffmann-La Roche AG, 2018.

     

    M-GB-00000980

    Date of preparation: September 2020

     

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2021 Roche Products Limited
    • 19.01.2021
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00002434 Date of Preparation January 2021.